Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral vinorelbine plus trastuzumab in first- and second-line treatment of women with metastatic HER2-positive breast cancer
2010-021618-42Phase 2Terminated
- Sponsor
- Vejle Hospital
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and trastuzumab in HER2-enriched breast cancer (HER2+) and breast cancer, sponsored by Vejle Hospital. Primary endpoint: Primary efficacy endpoint. Started Jul 2010; status: terminated.
02
Drugs
vinorelbinetrastuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)breast cancer
Beyond the preview
Go deeper on 2010-021618-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021618-42.